Three times weekly Versus daily dose α-interferon treatment in patients with acute hepatitis C [7]

American Journal of Gastroenterology

Volumn 97, Issue 2, 2002, Pages 492-493

  Fabris, Paolo ^a   Tositti, Giulia ^a   Giordani, Maria Teresa ^a   Infantolino, Domenico ^b   De Lalla, Fausto ^a  

^a SAN BORTOLO HOSPITAL   (Italy)

^b Castelfranco Veneto Hospital   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; RECOMBINANT ALPHA2A INTERFERON; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ADULT; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS C; HUMAN; LETTER; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROCONVERSION; SEX DIFFERENCE; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT OUTCOME; VIRUS TITRATION;

EID: 0036174782     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04070-9     Document Type: Letter

References (6)

1. Natural history of hepatitis C
2. Interferon as treatment for acute hepatitis C. A meta-analysis
3. Treatment of acute hepatitis C virus infection
4. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load
5. High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C. A pilot study
6. Alpha-2b IFN alone or in combination with Ketoprofen in naive patients with chronic hepatitis C